File Download
  Links for fulltext
     (May Require Subscription)
Supplementary

Article: Vaccinia virus-based multivalent H5N1 avian influenza vaccines adjuvanted with IL-15 confer sterile cross-clade protection in mice

TitleVaccinia virus-based multivalent H5N1 avian influenza vaccines adjuvanted with IL-15 confer sterile cross-clade protection in mice
Authors
Issue Date2009
PublisherAmerican Association of Immunologists. The Journal's web site is located at http://www.jimmunol.org
Citation
Journal Of Immunology, 2009, v. 182 n. 5, p. 3063-3071 How to Cite?
AbstractThe potential for a global influenza pandemic remains significant with epidemiologic and ecologic indicators revealing the entrenchment of the highly pathogenic avian influenza A H5N1 in both wild bird populations and domestic poultry flocks in Asia and in many African and European countries. Indisputably, the single most effective public health intervention in mitigating the devastation such a pandemic could unleash is the availability of a safe and effective vaccine that can be rapidly deployed for pre-exposure vaccination of millions of people. We have developed two vaccinia-based influenza vaccines that are molecularly adjuvanted with the immune stimulatory cytokine IL-15. The pentavalent Wyeth/IL-15/5Flu vaccine expresses the hemagglutinin, neuraminidase, and nucleoprotein derived from the H5N1 influenza virus A/Vietnam/1203/2004 and the matrix proteins M1 and M2 from the H5N1 A/CK/Indonesia/PA/2003 virus on the backbone of a currently licensed smallpox vaccine. The bivalent MVA/IL-15/HA/NA vaccine expresses only the H5 hemagglutinin and N1 neuraminidase on the modified vaccinia virus Ankara (MVA) backbone. Both vaccines induced cross-neutralizing Abs and robust cellular immune responses in vaccinated mice and conferred sterile cross-clade protection when challenged with the H5N1 virus of a different clade. In addition to having potential as a universal influenza vaccine, in the event of an impending pandemic the Wyeth/IL-15/5Flu is also readily amenable to bulk production to cover the global population. For those individuals for whom the use of the Wyeth vaccine is contraindicated, our MVA/IL-15/HA/NA offers a substitute or a prevaccine to be used in a mass vaccination campaign similar to the smallpox eradication campaigns of few decades ago.
Persistent Identifierhttp://hdl.handle.net/10722/59425
ISSN
2021 Impact Factor: 5.426
2020 SCImago Journal Rankings: 2.737
PubMed Central ID
ISI Accession Number ID
Funding AgencyGrant Number
National Cancel Institute
Center for Cancer Research
National Institutes of Health (NIH)HHSN206200700005C
National Institute of Allergy and Infections Diseases
Area of Excellence Scheme of the University Grants Committee Hong KongAoE/M-12/06
Funding Information:

This work was supported by the Intramural Research Program of the National Cancel Institute, Center for Cancer Research, National Institutes of Health (NIH), National Institute of Allergy and Infections Diseases, NIH Contract HHSN206200700005C, and Area of Excellence Scheme of the University Grants Committee Hong Kong Grant AoE/M-12/06.

References
Grants

 

DC FieldValueLanguage
dc.contributor.authorPoon, LLMen_HK
dc.contributor.authorLeung, YHCen_HK
dc.contributor.authorNicholls, JMen_HK
dc.contributor.authorPerera, PYen_HK
dc.contributor.authorLichy, JHen_HK
dc.contributor.authorYamamoto, Men_HK
dc.contributor.authorWaldmann, TAen_HK
dc.contributor.authorPeiris, JSMen_HK
dc.contributor.authorPerera, LPen_HK
dc.date.accessioned2010-05-31T03:49:50Z-
dc.date.available2010-05-31T03:49:50Z-
dc.date.issued2009en_HK
dc.identifier.citationJournal Of Immunology, 2009, v. 182 n. 5, p. 3063-3071en_HK
dc.identifier.issn0022-1767en_HK
dc.identifier.urihttp://hdl.handle.net/10722/59425-
dc.description.abstractThe potential for a global influenza pandemic remains significant with epidemiologic and ecologic indicators revealing the entrenchment of the highly pathogenic avian influenza A H5N1 in both wild bird populations and domestic poultry flocks in Asia and in many African and European countries. Indisputably, the single most effective public health intervention in mitigating the devastation such a pandemic could unleash is the availability of a safe and effective vaccine that can be rapidly deployed for pre-exposure vaccination of millions of people. We have developed two vaccinia-based influenza vaccines that are molecularly adjuvanted with the immune stimulatory cytokine IL-15. The pentavalent Wyeth/IL-15/5Flu vaccine expresses the hemagglutinin, neuraminidase, and nucleoprotein derived from the H5N1 influenza virus A/Vietnam/1203/2004 and the matrix proteins M1 and M2 from the H5N1 A/CK/Indonesia/PA/2003 virus on the backbone of a currently licensed smallpox vaccine. The bivalent MVA/IL-15/HA/NA vaccine expresses only the H5 hemagglutinin and N1 neuraminidase on the modified vaccinia virus Ankara (MVA) backbone. Both vaccines induced cross-neutralizing Abs and robust cellular immune responses in vaccinated mice and conferred sterile cross-clade protection when challenged with the H5N1 virus of a different clade. In addition to having potential as a universal influenza vaccine, in the event of an impending pandemic the Wyeth/IL-15/5Flu is also readily amenable to bulk production to cover the global population. For those individuals for whom the use of the Wyeth vaccine is contraindicated, our MVA/IL-15/HA/NA offers a substitute or a prevaccine to be used in a mass vaccination campaign similar to the smallpox eradication campaigns of few decades ago.en_HK
dc.languageengen_HK
dc.publisherAmerican Association of Immunologists. The Journal's web site is located at http://www.jimmunol.orgen_HK
dc.relation.ispartofJournal of Immunologyen_HK
dc.rightsThis is an author-produced version of a manuscript accepted for publication in The Journal of Immunology (The JI). The American Association of Immunologists, Inc. (The AAI), publisher of The JI, holds the copyright to this manuscript. This manuscript has not yet been copyedited or subjected to editorial proofreading by The JI; hence, it may differ from the final version published in The JI (online and in print). The AAI (The JI) is not liable for errors or omissions in this author-produced version of the manuscript or in any version derived from it by the National Institutes of Health or any other third party. The final, citable version of record can be found at www.jimmunol.org-
dc.subject.meshAdjuvants, Immunologic - administration and dosage-
dc.subject.meshInfluenza A Virus, H5N1 Subtype - classification - immunology-
dc.subject.meshInterleukin-15 - administration and dosage - immunology-
dc.subject.meshOrthomyxoviridae Infections - immunology - prevention and control-
dc.subject.meshVaccinia virus - genetics - immunology-
dc.titleVaccinia virus-based multivalent H5N1 avian influenza vaccines adjuvanted with IL-15 confer sterile cross-clade protection in miceen_HK
dc.typeArticleen_HK
dc.identifier.openurlhttp://library.hku.hk:4550/resserv?sid=HKU:IR&issn=0022-1767&volume=182&issue=5&spage=3063&epage=3071&date=2009&atitle=Vaccinia+virus-based+multivalent+H5N1+avian+influenza+vaccines+adjuvanted+with+IL-15+confer+sterile+cross-clade+protection+in+mice-
dc.identifier.emailPoon, LLM: llmpoon@hkucc.hku.hken_HK
dc.identifier.emailLeung, YHC: cyhleung@hkucc.hku.hken_HK
dc.identifier.emailNicholls, JM: jmnichol@hkucc.hku.hken_HK
dc.identifier.emailPeiris, JSM: malik@hkucc.hku.hken_HK
dc.identifier.authorityPoon, LLM=rp00484en_HK
dc.identifier.authorityLeung, YHC=rp00307en_HK
dc.identifier.authorityNicholls, JM=rp00364en_HK
dc.identifier.authorityPeiris, JSM=rp00410en_HK
dc.description.naturelink_to_OA_fulltext-
dc.identifier.doi10.4049/jimmunol.0803467en_HK
dc.identifier.pmid19234203-
dc.identifier.pmcidPMC2656349-
dc.identifier.scopuseid_2-s2.0-64849110995en_HK
dc.identifier.hkuros162147en_HK
dc.relation.referenceshttp://www.scopus.com/mlt/select.url?eid=2-s2.0-64849110995&selection=ref&src=s&origin=recordpageen_HK
dc.identifier.volume182en_HK
dc.identifier.issue5en_HK
dc.identifier.spage3063en_HK
dc.identifier.epage3071en_HK
dc.identifier.isiWOS:000263653100058-
dc.publisher.placeUnited Statesen_HK
dc.relation.projectControl of Pandemic and Inter-pandemic Influenza-
dc.identifier.scopusauthoridPoon, LLM=7005441747en_HK
dc.identifier.scopusauthoridLeung, YHC=26531438300en_HK
dc.identifier.scopusauthoridNicholls, JM=7201463077en_HK
dc.identifier.scopusauthoridPerera, PY=7006409051en_HK
dc.identifier.scopusauthoridLichy, JH=7005964360en_HK
dc.identifier.scopusauthoridYamamoto, M=7405303551en_HK
dc.identifier.scopusauthoridWaldmann, TA=35393178100en_HK
dc.identifier.scopusauthoridPeiris, JSM=7005486823en_HK
dc.identifier.scopusauthoridPerera, LP=7004465760en_HK
dc.identifier.citeulike4098119-
dc.identifier.issnl0022-1767-

Export via OAI-PMH Interface in XML Formats


OR


Export to Other Non-XML Formats